NEW YORK, March 8, 2016 /PRNewswire/ -- The following
statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise
acquired securities of Esperion Therapeutics, Inc.
("Esperion") (NASDAQ: ESPR) between August 18, 2015 and September 28, 2015.
You are hereby notified that a securities class action
lawsuit has been commenced in the USDC for the Eastern District of
Michigan. To get more information
go to: http://zlk.9nl.com/esperion-espr.
The complaint alleges that Defendants issued false and
misleading statements regarding the Company's business and
prospects, including that there was no clear path to approval for
ETC-1002, the Company's lead product candidate designed to lower
LDL-cholesterol levels, and that the FDA had encouraged the Company
to initiate a cardiovascular outcomes trial ("CVOT") and that
completion of a CVOT could be necessary prior to approval of
ETC-1002.
On August 17, 2015, Esperion
reported to investors material events from an August 2015 meeting with the FDA; the Company
stated that during the meeting it was informed by the FDA that the
Company would not have to complete a CVOT to gain approval of
ETC-1002. Then in a September 28,
2015 news release the Company noted that the FDA had
actually "encouraged the Company to initiate a cardiovascular
outcomes trial promptly" and it may be necessary to have a
completed CVOT prior to approval.
If you suffered a loss in Esperion you have until
March 14, 2016 to request that
the Court appoint you as lead plaintiff. Your ability to share in
any recovery doesn't require that you serve as a lead plaintiff. To
obtain additional information, contact Joseph E. Levi, Esq. either via email at
jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877)
363-5972, or visit http://zlk.9nl.com/esperion-espr.
Levi & Korsinsky is a national firm with offices in
New York, New Jersey, California, Connecticut, and Washington D.C. The firm's attorneys have
extensive expertise and experience representing investors in
securities litigation involving financial fraud, and have recovered
hundreds of millions of dollars for aggrieved shareholders.
Attorney advertising. Prior results do not guarantee similar
outcomes.
CONTACT:
Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY
10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
Logo -
http://photos.prnewswire.com/prnh/20120409/MM84375LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/investor-alert-levi--korsinsky-llp-notifies-shareholders-of-esperion-therapeutics-inc-of-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-march-14-2016--espr-300232494.html
SOURCE Levi & Korsinsky, LLP